and its antibody asset Mim8, with the Phase III FRONTIER2 trial (NCT05053139) in haemophilia A completing earlier this year. Novo Nordisk has not yet published data from the study. Novo Nordisk is ...

Novo Nordisk blueprints $1.2B rare disease production ... To take on Roche’s blockbuster, Novo is advancing Mim8, a bispecific antibody designed to bridge Factor IXa and X to replace missing ...

Novo Nordisk is diversifying its portfolio with treatments like Mim8 for hemophilia A. Mim8 has shown statistical significance in reducing treated bleeding episodes compared to no prophylaxis ...

A final decision is expected soon. Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon.

Under the program Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from ... interim phase 3 results evaluating safety profile and efficacy of Mim8 prophylaxis ...

The company’s haemophilia portfolio includes Alhemo (concizumab) and its antibody asset Mim8, with the Phase III FRONTIER2 trial (NCT05053139) in haemophilia A completing earlier this year. Novo ...

Novo Nordisk is diversifying its portfolio with treatments like Mim8 for hemophilia A. Mim8 has shown statistical significance in reducing treated bleeding episodes compared to no prophylaxis ...

For the first time this century, Novo Nordisk is breaking new ground in its home country ... Novo’s hemophilia pipeline also includes the Phase I Inno8 and the Phase III Mim8. Monday’s investment ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...